Maxcyte SEC Filings

MaxCyte, Inc. has regained compliance with Nasdaq’s minimum bid price rule. The company previously received a notice that its common stock had closed below $1.00 per share for 30 consecutive trading days, putting its Nasdaq Global Select Market listing at risk.

Nasdaq informed MaxCyte that for 10 consecutive business days, from May 27, 2026 to June 9, 2026, the closing bid price of its common stock was at or above $1.00. As a result, MaxCyte now complies with Nasdaq Listing Rule 5450(a)(1), and Nasdaq considers the matter closed.

River Global Investors LLP has disclosed a sizable stake in MaxCyte, Inc., reporting beneficial ownership of 6,529,027 equity shares, equal to about 6.1% of the company. River Global holds sole voting and dispositive power over these shares, meaning it alone decides how they are voted and when they are sold.

The position was built using investment capital from funds managed by River Global. On May 13, 2026, the firm bought 31,000 shares at 1.115 per share and 619,000 shares at 1.1142 per share through brokers in ordinary open-market trades, reinforcing its role as a financial investor rather than a strategic partner.

MaxCyte, Inc. reported first-quarter 2026 results showing lower revenue but a smaller loss as it reduced operating expenses. Revenue was $9.7 million versus $10.4 million a year earlier, driven by weaker core product and license sales, partly offset by higher milestone and royalty revenue.

Core revenue fell to $6.2 million, mainly from lower processing assembly and license revenue, while Strategic Platform License milestones and royalties rose to $3.4 million. Gross margin remained high at 84%. The net loss narrowed to $4.8 million from $10.3 million as research, sales, and administrative costs declined.

MaxCyte ended March 31, 2026 with cash and cash equivalents of $14.6 million, short-term investments of $92.3 million, and long-term investments of $40.8 million. Management states that existing cash, investments, and operating cash flows are expected to fund operations for at least 12 months while it continues investing in its ExPERT cell engineering platform and new products such as the ExPERT DTx.

MaxCyte, Inc. reported first quarter 2026 revenue of $9.7 million, made up of $6.2 million in core revenue and $3.4 million from Strategic Platform License (SPL) program milestones and royalties. Total revenue declined 7% year over year, but the net loss improved to $4.8 million, or $0.04 per share, from $10.3 million a year earlier as operating expenses were reduced.

The company reiterated its full year 2026 revenue guidance of $30–32 million, including core revenue of $25–27 million and SPL program-related revenue of $5 million. MaxCyte’s board authorized a $10 million share repurchase program over one year, while the balance sheet showed total assets of $194.5 million and stockholders’ equity of $167.9 million as of March 31, 2026.

MaxCyte, Inc. is asking stockholders to elect three Class II directors—Patrick Balthrop, Cynthia Collins, and Stanley Erck—to serve until the 2029 annual meeting, and to ratify CohnReznick LLP as independent auditor for the year ending December 31, 2026.

The 2026 annual meeting will be held on June 17, 2026 at 11:00 a.m. Eastern Time in Rockville, Maryland, for holders of 107,121,672 common shares outstanding as of April 21, 2026. The board reports that eight of nine directors are Nasdaq‑independent and is led by an independent non‑executive chair, Richard Douglas.

For 2025, CEO Maher Masoud received total compensation of $2,687,657, including salary, equity awards, and an annual bonus funded at 88.5% of target, based on goals tied to revenue, EBITDA and operational milestones. Major stockholders include Capricorn Fund Managers (7.7%), BlackRock (6.5%), and River Global Investors (5.1%).

Ahuja Parmeet reported acquisition or exercise transactions in this Form 4 filing.

MAXCYTE, INC. Chief Financial Officer Parmeet Ahuja reported an equity award of 187,500 shares of Common Stock in the form of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of common stock at no purchase price.

According to the filing, 25% of the RSUs will vest on March 30, 2027, and the remaining RSUs will vest in three equal annual installments after that date, subject to Ahuja’s continued service with the company through each vesting date. Following this grant, Ahuja directly holds 187,500 shares reported in this Form 4.

MAXCYTE, INC. Chief Financial Officer Parmeet Ahuja received a grant of employee stock options covering 375,000 shares of Common Stock. The options have an exercise price of $0.6762 per share and expire on March 29, 2036.

According to the vesting schedule, 25% of the shares underlying this option vest on March 30, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, contingent on continued service. Following this grant, Ahuja holds 375,000 stock options directly.

MAXCYTE, INC. filed an initial insider ownership report for Parmeet Ahuja, who serves as Chief Financial Officer. This Form 3 establishes Ahuja as a reporting person for future disclosures of any holdings or transactions in MAXCYTE, INC. securities, but does not itself report any transactions or share ownership changes.